李 婉如

Medicine & Life Sciences

1. Macular Degeneration 100%
2. Ranibizumab 83%
3. Cohort Studies 67%
4. aflibercept 63%
5. Eye 61%
6. Optic Neuritis 49%
7. Vascular Endothelial Growth Factor A 48%
8. Population 38%
9. Cavernous Sinus 36%
10. Retinal Vein Occlusion 35%
11. Inclusion Conjunctivitis 34%
12. Retrospective Studies 34%
13. Carotid-Cavernous Sinus Fistula 32%
14. Tolosa-Hunt Syndrome 32%
15. Ocular Toxoplasmosis 30%
16. Retinal Detachment 29%
17. Azure Stains 29%
18. Ocular Vision 28%
19. Immunoglobulin Light-chain Amyloidosis 26%
20. Confidence Intervals 24%
21. Adrenal Cortex Hormones 24%
22. Visual Acuity 23%
23. Amyloidosis 21%
24. Stroke 18%
25. Systemic Lupus Erythematosus 18%
26. Aspirin 17%
27. Retinal Diseases 17%
28. Vaccination 15%
29. Colorectal Neoplasms 15%
30. Meta-Analysis 14%
31. Systematic Reviews 14%
32. Randomized Controlled Trials 13%
33. Odds Ratio 12%
34. Diplopia 12%
35. Incidence 11%
36. Eye Manifestations 11%
37. Foreign Bodies 10%
38. Real-Time Polymerase Chain Reaction 10%
39. Mortality 9%
40. Biopsy 9%
41. Allergic Conjunctivitis 8%